ASCO® 2023 Insights: "Zanubrutinib + Obinutuzumab vs. Obinutuzumab in Patients With R/R FL - Updated Analysis of the ROSEWOOD Study"

493 views
June 9, 2023
0 Comments
Login to view comments. Click here to Login